Abstract
Enzyme replacement therapy (ERT) has revolutionized treatment for patients with LSDs, currently available for Mucopolysaccharidosis I (MPS I), MPS II, MPS IV, MPS VI, Gaucher disease, Fabry disease, and Pompe disease. The therapeutic enzyme replacement effectively lowers substrate accumulation and has dramatically improved lifespan, increased overall quality of life, and diminished the extent of organ involvement in these conditions. Despite this progress, therapeutic deficiencies are evidenced in the different LSDs due to various factors: minimal or no enzyme delivery to all necessary target sites; delayed diagnosis resulting in irreversible substrate buildup and clinical consequences prior to starting ERT; inability of the therapeutic enzyme to reach certain sanctuary sites, nor pass blood–brain barrier; and immune responses abrogating treatment effectiveness. Present efforts towards bridging the gap between currently available therapies and a cure for LSDs are best viewed through the lens of our collective experience with Pompe disease. While ERT dramatically improved the prognosis in both infantile and later onset forms of Pompe disease, several limitations exist: the inefficiency of ERT distribution and uptake in the target muscular system, the inability of ERT to cross the blood-brain barrier, the presence of pathological preconditions or the degree of muscular and lysosomal damage, the presence of defective cellular machinery or autophagy, and the development of anti-rhGAA IgG antibodies against ERT. Dosage is also an issue as cases of clinical plateau and decline have been documented on standard doses followed by subsequent improvements with higher doses. The shortcomings and adverse effects of current therapies emphasize the need for therapeutic enhancements in addition to or in place of ERT such as immunomodulation, adjunctive therapies, reduction of defective autophagy, small molecule chaperone therapy, second generation (biobetter) ERT, and gene therapy to supplant current methods.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Anderson LJ, Henley W, Wyatt KM, Nikolaou V, Waldek S, Hughes DA, Pastores GM, Logan S (2014) Long-term effectiveness of enzyme replacement therapy in children with Gaucher disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 37(6):961–968
Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, Chen YT, Rosenberg AS, Kishnani PS (2011) The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med 13(8):729–736
Banugaria SG, Prater SN, McGann JK, Feldman JD, Tannenbaum JA, Bailey C, Gera R, Conway RL, Viskochil D, Kobori JA, Rosenberg AS, Kishnani PS (2013a) Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med 15(2):123–131
Banugaria SG, Prater SN, Patel TT, Dearmey SM, Milleson C, Sheets KB, Bali DS, Rehder CW, Raiman JA, Wang RA, Labarthe F, Charrow J, Harmatz P, Chakraborty P, Rosenberg AS, Kishnani PS (2013b) Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One 8(6):e67052
Barton NW, Brady RO, Damrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 324:1464–1470
Bennett LL, Mohan D (2013) Gaucher disease and its treatment options. Ann Pharmacother 47(9):1182–1193. doi:10.1177/1060028013500469
Burton BK (2012) Newborn screening for Pompe disease: an update, 2011. Am J Med Genet C Semin Med Genet 160C(1):8–12
Chien YH, Lee NC, Huang HJ, Thurberg BL, Tsai FJ, Hwu WL (2011) Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening. J Pediatr 158(6):1023–1027.e1
Chien YH, Hwu WL, Lee NC (2013) Pompe disease: early diagnosis and early treatment make a difference. Pediatr Neonatol 54(4):219–227, Epub 2013 Apr 28
Clarke L, Wraith JE, Beck M et al (2009) Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123:229–240
de Vries JM, van der Beek NA, Kroos MA, Ozkan L, van Doorn PA, Richards SM, Sung CC, Brugma JD, Zandbergen AA, van der Ploeg AT, Reuser AJ (2010) High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 101(4):338–345, Epub 2010 Aug 14
Desnick RJ (2004) Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27(3):385–410
Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ, International Collaborative Fabry Disease Study Group (2001) Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16
Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS (2008) Chemically modified β-glucuronidase crosses blood–brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci 105(7):2616–2621
Hollak CE, Wijburg FA (2014) Treatment of lysosomal storage disorders: successes and challenges. J Inherit Metab Dis 37(4):587-598
Jones HN, Muller CW, Lin M, Banugaria SG, Case LE, Li JS, O’Grady G, Heller JH, Kishnani PS (2010) Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 25(4):277–283
Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile onset Pompe disease. Neurology 68:99–109
Kishnani PS, Goldenberg PC, DeArmey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen YT (2010) Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99(1):26–33
Kishnani PS, Beckemeyer AA, Mendelsohn NJ (2012) The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet 160(10):1–7
Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai K, Urashima T, Ijima M, Fujiwara M, Kaneshiro E, Ohashi T, Eto Y, Ishigaki K, Osawa M, Kyosen SO, Ida H (2010) Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Mol Genet Metab 100(1):14–19
Lacaná E, Yao LP, Pariser AR, Rosenberg AS (2012) The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease. Am J Med Genet C Semin Med Genet 160C(1):30–39
Liao HC, Chiang CC, Niu DM, Wang CH, Kao SM, Tsai FJ, Huang YH, Liu HC, Huang CK, Gao HJ, Yang CF, Chan MJ, Lin WD, Chen YJ (2014) Detecting multiple lysosomal storage diseases by tandem mass spectrometry – a national newborn screening program in Taiwan. Clin Chim Acta 431:80–86, Epub 2014 Feb 7
Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66(4):1589–1595
Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, Kishnani PS (2012) Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med 14(1):135–142
Muenzer J (2014) Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab 111(2):63-72
Muenzer J, Wraith JE, Beck M et al (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med 8:465–473
Nascimbeni AC, Fanin M, Masiero E, Angelini C, Sandri M (2012) Impaired autophagy contributes to muscle atrophy in glycogen storage disease type II patients. Autophagy 8(11):1697–1700. doi:10.4161/auto.21691, Epub 2012 Aug 31
Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger CJ, Robinson PH, Loo JC, Smitka M, Jardine P, Tatò L, Chabrol B, McCandless S, Kimura S, Mehta L, Bali D, Skrinar A, Morgan C, Rangachari L, Corzo D, Kishnani PS (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11(3):210–219
Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39(3):215–224. doi:10.1111/jcpt.12136, Epub 2014 Feb 25
Pieroni M, Camporeale A, Della Bona R, Sabini A, Cosmi D, Magnolfi A, Bolognese L (2013) Progression of Fabry cardiomyopathy despite enzyme replacement therapy. Circulation 128(15):1687–1688
Poll LW, Vom Dahl S (2009) Image of the month. Hepatic Gaucheroma mimicking focal nodular hyperplasia. Hepatology 50(3):985–986
Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul C, Wang RY, Young SP, Kishnani PS (2012) The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med 14(9):800–810
Prater SN, Patel TT, Buckley AF, Mandel H, Vlodavski E, Banugaria S, Feeney EJ, Raben N, Kishnani PS (2013) Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy. Orphanet J Rare Dis 8:90
Raben N, Danon M, Gilbert AL, Dwivedi S, Collins B, Thurberg BL, Mattaliano RJ, Nagaraju K, Plotz PH (2003) Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 80(1–2):159–169
Raben N, Fukuda T, Gilbert AL et al (2005) Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther 11:48–56
Raben N, Takikita S, Pittis MG, Bembi B, Marie SK, Roberts A, Page L, Kishnani PS, Schoser BG, Chien YH, Ralston E, Nagaraju K, Plotz PH (2007) Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand…. Autophagy 3(6):546–552, Epub 2007 Jun 15
Raben N, Ralston E, Chien YH, Baum R, Schreiner C, Hwu WL, Zaal KJ, Plotz PH (2010) Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implications for therapy. Mol Genet Metab 8:324–331
Raben N, Wong A, Ralston E, Myerowitz R (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet 160C(1):13–21
Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E (2005) Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood 105(12):4569–4572
Schiffmann R, Fitzgibbon EJ, Harris C, DeVile C, Davies EH, Abel L, van Schaik IN, Benko W, Timmons M, Ries M, Vellodi A (2008) Randomized, controlled trial of miglustat in Gaucher’s disease type 3. Ann Neurol 64(5):514–522
Shea L, Raben N (2009) Autophagy in skeletal muscle: implications for Pompe disease. Int J Clin Pharmacol Ther 47(Suppl 1):S42–S47
Shigeto S, Katafuchi T, Okada Y, Nakamura K, Endo F, Okuyama T, Takeuchi H, Kroos MA, Verheijen FW, Reuser AJ, Okumiya T (2011) Improved assay for differential diagnosis between Pompe disease and acid α-glucosidase pseudodeficiency on dried blood spots. Mol Genet Metab 103(1):12–17, Epub 2011 Jan 22
Spiridigliozzi GA, Heller JH, Kishnani PS, Van der Ploeg AT, Ebbink BJ, Aarsen FK, van Gelder CM, Van den Hout JMP (2013) Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. Neurology 80(12):1173–1173
Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Müller-Felber W, Mengel E, Spranger M, Schoser B (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257(1):91–97
Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O’Callaghan M (2006) Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 8:1208–1220
Valayannopoulos V, Wijburg FA (2011) Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 50(Suppl 5):v49–v59
Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274(4):331–341, Epub 2013 May 6
Weidemann F, Krämer J, Duning T, Lenders M, Canaan-Kühl S, Krebs A, González HG, Sommer C, Uçeyler N, Niemann M, Störk S, Schelleckes M, Reiermann S, Stypmann J, Brand SM, Wanner C, Brand E (2014) Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol 25(4):837–849
Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT (2004) Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 55(4):495–502
Yanovitch TL, Casey R, Banugaria SG, Kishnani PS (2010) Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease. J Neuroophthalmol 30(2):165–166
Zhu Y, Li X, Kyazike J, Zhou Q, Thurberg BL, Raben N, Mattaliano RJ, Cheng SH (2004) Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice. J Biol Chem 279(48):50336–50341, Epub 2004 Sep 21
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Kishnani, P.S. (2015). Challenges of Enzyme Replacement Therapy: Poor Tissue Distribution in Lysosomal Diseases Using Pompe Disease as a Model. In: Rosenberg, A., Demeule, B. (eds) Biobetters. AAPS Advances in the Pharmaceutical Sciences Series, vol 19. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2543-8_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2543-8_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2542-1
Online ISBN: 978-1-4939-2543-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)